Title
Search
All Issues
6
Year: 2014  Vol. 18   Num. Suppl. 2  - undefined
DOI: 10.1055/s-0034-1395267
Print:
Versão em PDF PDF in English TextoText in English
Nuances in the Treatment of Malignant Tumors of the Clival and Petroclival Region
Author(s):
Ahmed Mohyeldin, Daniel M. Prevedello, Ali O. Jamshidi, Leo F.S. Ditzel Filho, Ricardo L. Carrau
Key words:
skull base - malignancy - clival - petroclival - endoscopic endonasal - craniotomy - chordoma - chondrosarcoma - plasmacytoma
Abstract:

Introduction Malignancies of the clivus and petroclival region are mainly chordomas and chondrosarcomas. Although a spectrum of malignancies may present in this area, a finite group of commonly encountered malignant pathologies will be the focus of this review, as they are recognized to be formidable pathologies due to adjacent critical neurovascular structures and challenging surgical approaches.

Objectives The objective is to review the literature regarding medical and surgical management of malignant tumors of the clival and petroclival region with a focus on clinical presentation, diagnostic identification, and associated adjuvant therapies. We will also discuss our current treatment paradigm using endoscopic, open, and combined approaches to the skull base.

Data Synthesis A literature review was conducted, searching for basic science and clinical evidence from PubMed, Medline, and the Cochrane Database. The selection criteria encompassed original articles including data from both basic science and clinical literature, case series, case reports, and review articles on the etiology, diagnosis, treatment, and management of skull base malignancies in the clival and petroclival region.

Conclusions The management of petroclival malignancies requires a multidisciplinary team to deliver the most complete surgical resection, with minimal morbidity, followed by appropriate adjuvant therapy. We advocate the combination of endoscopic and open approaches (traditional or minimally invasive) as required by the particular tumor followed by radiation therapy to optimize oncologic outcomes.

  Print:

 

All right reserved. Prohibited the reproduction of papers
without previous authorization of FORL © 1997- 2024